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Background: Extracellular matrix protein PCPE2 is linked to alterations in HDL size and concentration.
Results: PCPE2 protects against diet-induced atherosclerosis by promoting HDL catabolism, reverse cholesterol transport, and
SR-BI-mediated uptake of HDL-cholesteryl ester.
Conclusion: PCPE2 mediates HDL function by reducing lipid and immune cell accumulation in the artery.
Significance: These findings establish a role for the extracellular matrix glycoprotein PCPE2 in SR-BI-mediated HDL function
and the prevention of atherosclerosis.
Studies in human populations have shown a significant corre-
lation between procollagen C-endopeptidase enhancer protein
2 (PCPE2) single nucleotide polymorphisms and plasma HDL
cholesterol concentrations. PCPE2, a 52-kDa glycoprotein
located in the extracellular matrix, enhances the cleavage of
C-terminal procollagen by bone morphogenetic protein 1
(BMP1). Our studies here focused on investigating the basis for
the elevated concentration of enlarged plasma HDL in PCPE2-
deficient mice to determine whether they protected against
diet-induced atherosclerosis. PCPE2-deficient mice were
crossed with LDL receptor-deficient mice to obtain LDLr/,
PCPE2/ mice, which had elevated HDL levels compared with
LDLr/ mice with similar LDL concentrations. We found that
LDLr/, PCPE2/ mice had significantly more neutral lipid
and CD68 infiltration in the aortic root than LDLr/ mice.
Surprisingly, in light of their elevated HDL levels, the extent of
aortic lipid deposition in LDLr/, PCPE2/ mice was similar
to that reported for LDLr/, apoA-I/ mice, which lack any
apoA-I/HDL. Furthermore, LDLr/, PCPE2/ mice had
reduced HDL apoA-I fractional clearance and macrophage to
fecal reverse cholesterol transport rates compared with
LDLr/ mice, despite a 2-fold increase in liver SR-BI expres-
sion. PCPE2 was shown to enhance SR-BI function by increasing
the rate of HDL-associated cholesteryl ester uptake, possibly by
optimizing SR-BI localization and/or conformation. We con-
clude that PCPE2 is atheroprotective and an important compo-
nent of the reverse cholesterol transport HDL system.
In humans there is an inverse correlation between the con-
centration of plasma HDL and the relative risk of developing
cardiovascular disease (CVD)5 (1– 4). To explain this associa-
tion, many studies have suggested that HDL plays a central role
in the pathway called reverse cholesterol transport (RCT), a
process that returns cholesterol to the liver for excretion (5, 6).
In the first step, ATP-binding cassette transporter A1 (ABCA1)
lipidates apoA-I with phospholipid and cholesterol to form na-
scent HDL (nHDL) (5, 7–9). These nHDL are rapidly converted
to mature HDL by plasma lecithin-cholesterol acyltransferase,
an enzyme that esterifies free cholesterol yielding mature
spherical HDL particles with a cholesteryl ester (CE)-rich core.
The RCT pathway is complete when the scavenger receptor
class B1 (SR-BI) in the liver removes CE from mature HDL,
leaving lipid-poor apoA-I to be recycled or filtered by the kid-
ney (10). Because the liver is the primary site of HDL metabo-
* This work was supported, in whole or in part, by National Institutes of Health
Grants NHLBI HL-112270, HL 112276, and HL 127649 (to M. G. S.-T.). This
work was also supported by American Heart Association Grants
09GRNT2280053 and 14GRNT20500029 (to M. J. T.). The authors declare
that they have no conflicts of interest with the contents of this article.
1 Supported by National Institutes of Health Diversity Supplement Grant
HL112270A1S1.
2 Supported by post-doctoral American Heart Association Grant
13POST17000005.
3 Supported by National Institutes of Health Grant RO1-HL058012.
4 To whom correspondence should be addressed: Dept. of Medicine, Div. of
Endocrinology, Metabolism, and Clinical Nutrition, Medical College of Wis-
consin, 8701 W. Watertown Plank Rd., Milwaukee, WI 53226. Tel.: 414-955-
5728; Fax: 414-456-6312; E-mail: msthomas@mcw.edu.
5 The abbreviations used are: CVD, cardiovascular disease; RCT, reverse cho-
lesterol transport; ABCA1, ATP-binding cassette transporter A1; nHDL, na-
scent HDL; CE, cholesteryl ester; SR-BI, scavenger receptor class B1; PCPE2,
procollagen C-endopeptidase enhancer protein 2; BMP1, bone morpho-
genetic protein 1; NTR, netrin-like; OCT, optimal cutting temperature
(medium); 3H-COE, cholesteryl [1a,2a-3H]oleoyl ether; FCR, fractional cata-
bolic rate.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 290, NO. 25, pp. 15496 –15511, June 19, 2015
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
15496 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 290 • NUMBER 25 • JUNE 19, 2015
 by guest on N
ovem
ber 23, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
lism, the steady-state concentration of plasma HDL depends
largely on the rate of nHDL formation balanced by the catabo-
lism of HDL.
For some time, epidemiology studies used plasma HDL con-
centration to help calculate the relative risk of developing CVD.
That approach has been criticized because plasma HDL con-
centration does not adequately predict an individual’s CVD risk
(11, 12). Recent studies have shown that an individual’s choles-
terol efflux capacity is a more accurate measure of assessing
CVD risk (13–15). Efflux capacity measures the potential of an
individual’s apoB-depleted plasma to mobilize cellular choles-
terol, suggesting that the inherent properties of one’s plasma
HDL are responsible for driving this process.
Cholesterol efflux is an essential physiological process that
produces nHDL particles. It is now recognized that the compo-
sition and structure of nHDL, before modification in plasma,
differ significantly from plasma or mature HDL. These nHDL
particles contain three apoA-I monomers and are highly
enriched in free cholesterol and sphingomyelin, having a com-
position similar to lipid rafts (16).
nHDL formation is not a spontaneous process occurring
when apoA-I and phospholipid come in contact. Rather,
nHDL formation requires carefully orchestrated conforma-
tional changes in the apoprotein structure that permit shielded,
hydrophobic residues within multiple monomers of apoA-I to
become accessible and bind phospholipid (16). This process
yields 11-nm diameter nHDL particles carrying over 100
molecules of free cholesterol/particle (17), an efficient process
to efflux cholesterol from the cell.
Several mechanisms have been proposed to explain how
nHDL is assembled via ABCA1 on the membrane surface (7, 18,
19). One hypothesis has binding of lipid-poor apoA-I to ABCA1
as the first step in the process. However, other studies suggest
that low affinity, high capacity membrane binding sites are
involved before apoA-I binds to ABCA1 (20 –23). Interaction
between apoA-I and membrane-bound accessory protein(s)
could potentially promote conformational changes within lip-
id-poor apoA-I and in so doing enhance the rate of nHDL par-
ticle formation (12, 24, 25).
Recent reports suggest that procollagen C-endopeptidase
enhancer protein 2 (PCPE2) participates in promoting choles-
terol efflux. A connection between PCPE2 and HDL was
inferred when significant correlations were observed between
PCPE2 single nucleotide polymorphisms and plasma HDL cho-
lesterol concentrations (26). PCPE2 is a 52-kDa glycoprotein
encoded by the PCOLCE2 gene (27, 28). It shares 43% amino
acid sequence identity with PCPE1 (29). Both PCPE1 and
PCPE2 are located in the extracellular matrix, where they facil-
itate bone morphogenetic protein 1 (BMP1) cleavage of C-ter-
minal procollagen propeptides. PCPE2 and PCPE1 have dif-
ferent tissue distributions and heparin-binding affinities,
suggesting a functional divergence (29). PCPE2 is heavily
expressed in heart tissue in contrast to PCPE1. Both PCPE1 and
PCPE2 have two CUB (Complement C1r/C1s, Uegf, Bmp1)
domains separated by a short linker region (30 –32), with each
domain consisting of about 110 residues containing a -sand-
wich fold that mediates a variety of protein-protein interac-
tions. The CUB domains also contain a homologous Ca2 bind-
ing site that mediates ionic interactions between protein
partners, similar to that described in the low-density lipopro-
tein receptor family (33). The tandem CUB domains are fol-
lowed by a C-terminal netrin-like (NTR) domain (27, 29). CUB
domains are commonly found in extracellular membrane pro-
teins that mediate protein-protein interactions (33–36),
whereas NTR domains bind to cell surface glycosaminoglycans
(37, 38), presumably anchoring PCPE2 to the extracellular
matrix.
Interestingly, BMP1, in addition to catalyzing procollagen
processing, removes the apoA-I six-amino acid propeptide (39).
Studies by Francone and others (26, 40, 41) show that PCPE2
stabilizes a ternary catalytic complex with apoA-I and BMP1.
These findings suggest that BMP1-PCPE2 processing of the
apoA-I propeptide might stimulate nHDL assembly (42).
Studies in PCPE2-deficient mice provide the first direct
experimental evidence linking PCPE2 to HDL metabolism (43).
PCPE2 knock-out mice had elevated concentrations of en-
larged plasma HDL (44), despite displaying defective ABCA1-
mediated cholesterol efflux capacity. Thus, reduced cholesterol
efflux is paradoxically associated with elevated plasma HDL
cholesterol in PCPE2-deficient mice. A recent genome-wide
siRNA screen also suggests that PCPE2 affects the efficiency of
HDL apoA-I secretion (45).
Because elevated plasma HDL levels are associated with
reduced atherosclerosis, we sought to investigate whether ele-
vated concentrations of enlarged HDL in PCPE2-deficient mice
were atheroprotective or atherogenic. We have suggested
mechanisms to explain the role of PCPE2 and provided evi-
dence demonstrating the participation of PCPE2 in HDL cho-
lesterol catabolism and reverse cholesterol transport.
Experimental Procedures
Animals and Diets—PCPE2-deficient mice in the C57BL/6
background were obtained from the Max Planck Institute (43)
and then crossed with LDLr/ mice to generate LDLr/,
PCPE2/ mice. Both LDLr/ and LDLr/, apoA-I/ mice
have been fully crossed onto the C57BL/6 background as
described previously (46, 47). Starting at 6 weeks of age, mice
were fed for 12 weeks either a standard chow diet or an athero-
genic diet containing 0.1% cholesterol and 10% calories from
palm oil (47). Mice were fasted for 3 h prior to being anesthe-
tized with ketamine/xylazine (200 mg/kg ketamine and 10
mg/kg xylazine) followed by euthanasia and blood collection
by cardiac puncture. The Animal Care and Use Committee
of the Wake Forest University School of Medicine approved
all procedures used in the current study. All mice were
housed in a temperature-controlled room and maintained in
a 12-h light/12-h dark cycle at the Wake Forest School of
Medicine vivarium.
Plasma Lipoprotein Isolation and Characterization—Blood
was collected in EDTA containing tubes then centrifuged at
15 °C for 10 min at 7000 rpm. The plasma fraction was collected
and stored at 80 °C. Total plasma cholesterol (Wako Diagnos-
tics Cholesterol E) was determined using an enzymatic assay
kit. For total lipoprotein cholesterol distribution, 15 g of total
plasma cholesterol was applied to a Superose 6 10/300GL col-
umn (GE Healthcare) with online mixing of enzymatic reagent
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(Cholesterol (Liquid) Reagents Set, Pointe Scientific Inc.) as
described previously (48). Isolation of the total lipoprotein frac-
tion for compositional analysis was carried out by first obtain-
ing the d  1.225 g/ml fraction after density gradient ultracen-
trifugation using KBr as described previously (46). The d 
1.225 g/ml fractions were separated into lipoprotein classes
using size-exclusion fast protein liquid chromatography
(FPLC) (46). Aliquots corresponding to VLDL, LDL, and HDL
classes were pooled and stored at 80 °C for composition anal-
ysis or used immediately for particle size determination. The
HDL particle size was determined by a comparison with stan-
dards of known Stokes diameter following separation using
Novex (Life Technologies) 4 –20% non-denaturing gels and
then stained with Coomassie Blue G-250 dye as described pre-
viously (49). Mouse plasma apoA-I concentration was mea-
sured using an enzyme-linked immunosorbent assay as
described previously (49).
Quantification of Pro-apolipoprotein A-I by Mass Spec-
trometry—The abundance of pro-apoA-I and apoA-I was
assessed from purified HDL and whole plasma from PCPE2/
and C57BL/6 mice using liquid chromatography-tandem mass
spectrometry. Whole plasma aliquots were separated on 12%
SDS-PAGE as described previously (16, 50 –52). The gel was
stained with SimplyBlue (Life Technologies), and the protein
band corresponding to 28,000 Da was excised from the gel,
minced, and repeatedly dehydrated with acetonitrile. The gel
pieces were rehydrated with a cold, freshly prepared solution
containing 20 ng/l trypsin in 10 mM ammonium bicarbonate,
pH 7.8, 0.1% (w/v) RapiGest SFTM, and 1 mM CaCl2. The final
trypsin to apoA-I mass ratio was 1:20. After incubation on ice
for 10 min, the digests were incubated for 18 h at 37 °C. The
digestion solution was removed, and gel pieces were covered
with 200 l of acetonitrile/formic acid/water (v/v/v, 50:5:45).
After sitting for 10 min the solvent was transferred to a fresh
tube. The extraction was repeated and the combined aliquots
acidified to an HCl:apoA-I ratio of 1:10 (v/v) using 500 mM HCl.
After the acidified solution was incubated for 35 min at 37 °C,
the sample was centrifuged for 10 min at 13,000 rpm. The
supernatant was transferred to a fresh tube before mass spec-
trometry. Survey scans were performed on each peptide mix-
ture using a Waters Q-TOF API-US mass spectrometer
equipped with a Waters CapLC and Advion Nanomate source.
Acquisition was controlled using Mass-LynxTM 4.0 software.
Peptides were loaded onto a PLRP-S trapping column, 0.5-mm
diameter  2.0-mm length, containing 3-m diameter parti-
cles with a pore diameter of 100 Å. Peptides were loaded onto
the trapping column in water/acetonitrile/formic acid (97:3:
0.2) at 500 nl/min. After switching of the trapping column, in-
line separation was accomplished on a 0.3  150-mm PCRP-S
column packed with 3-m diameter particles with 100 Å pores
at 470 nl/min. The following gradient elution was used: solvent
A (25 mM formic acid in 97% water and 3% acetonitrile) and
solvent B solvent B (25 mM formic acid in 3% water 97% aceto-
nitrile). The gradient profile was: 2% solvent B for 3 min with a
linear increase to 40% B at 90 min and then to 80% B in 5 min. At
95 min, the composition was ramped to 2% B over 5 min and
equilibrated with 2% B for 30 min. Positive ion survey scans
were recorded in the continuum mode with a scan window of
300 to 1500 m/z for 2 s. The source temperature was 80 °C and
cone voltage was 45 V. Experimental m/z was corrected using
mouse apoA-I tryptic fragment 7, m/z  533.7462. Ions within
0.051 m/z of the theoretical ions were sequenced. Product ion
MS/MS spectra were acquired in the continuum mode from 50
to 1500 m/z using a data-directed charge state-selective colli-
sion energy and an accumulation time of 2 s. Sequence analysis
of the MS/MS spectra was performed with a fragment ion tol-
erance of 0.05 m/z.
For quantification of the ratio of mature and pro-apoA-I, the
N-terminal tryptic peptides for mouse pro-apoA-I (WHV-
WQQDEPQSQWDK, protonated m/z  1996.8942) and
mature mouse apoA-I (DEPQSQWDK, protonated m/z 
1132.4911) were synthesized (GenScript), and the m/z, purity,
and sequence were verified by mass spectrometry. The reten-
tion time, mass, and sequence were used to identify the N-ter-
minal sequence from all samples analyzed.
For the analysis of intact pro- or mature mouse apoA-I from
purified HDL, mass spectrometric analysis was performed
using a Waters Q-TOF equipped with an Advion Triversa
Nanomate source as described previously (53). Samples (0.4
M) were prepared in 1:1 (v:v) acetonitrile-water containing
0.2% formic acid and then introduced into the mass spectrom-
eter at 500 nl/min. Acquisition parameters were adjusted to
maximize resolution.
Lipid Composition—Total and free cholesterol determina-
tion were performed on aliquots from FPLC-separated and
pooled HDL that had been spiked with the internal standard,
cholesterol-3,4-13C2 (Sigma-Aldrich), and subjected to lipid
extraction as previously described (16). To measure free cho-
lesterol an aliquot was removed, evaporated under argon, dis-
solved in hexane and then injected on a Finnigan TSQ Quan-
tum XLS tandem mass spectrometer interfaced to a TRACE gas
chromatograph (GC-MS/MS), as described previously (16, 47),
by select reaction monitoring (SRM) with the following param-
eters in the positive ion mode: scan time, 0.1 s; collision energy,
10 V; emission current, 25 A; electron energy, 42 eV; source
and transfer line temperature, 260 °C; and flow rate, 1 ml/min.
Analysis was carried out using a DB-1 column (10.4 m, 250 m
inner diameter) with a 0.25-M film thickness. For quantifying
total cholesterol, the remaining sample was dried under a
stream of nitrogen, redissolved in 1 ml of ethanol, mixed with
100 l of 50% (w/w) aqueous potassium hydroxide, and then
saponified for 1 h at 60 °C. After extraction, total cholesterol
was measured on the Quantum XLS. Cholesteryl ester was cal-
culated as the difference between free cholesterol and total
cholesterol.
Plasma triglycerides were analyzed using mass spectrometry
from mouse plasma after preliminary separation from other
polar and nonpolar lipids using aminopropyl solid-phase
extraction columns using the procedure of Kaluzny et al. (54)
with minor modifications. The nonpolar fraction was dried
under nitrogen and loaded onto the second solid-phase extrac-
tion column dissolved in 500 l of hexane. Cholesteryl esters
were removed from the column with 3– 4-ml washes of 4%
CH2Cl2 in hexane. Then triglycerides were eluted with 3– 8-ml
washes of CH2Cl2:diethyl ether:hexane (14:1:84). Quantitation
was by gas chromatography-mass spectrometry after saponifi-
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cation to generate methylated fatty acids (55, 56). The fatty
acids were quantified to obtain the total fatty acid composition.
The moles of fatty acids were summed and divided by 3 to
obtain the number of moles of triglyceride. C17 triglyceride was
used as the internal standard.
RNA Isolation, cDNA Synthesis, and Quantitative
Real-Time-PCR—Tissues harvested at necropsy were flash-fro-
zen with liquid nitrogen and kept at 80 °C until needed.
Briefly, tissue was quickly thawed, weighed, and then added to a
14-ml screw cap polypropylene tube containing 1 ml of pre-
chilled TRIzol (Life Technologies). The tissue was immediately
homogenized using a Polytron PT 1200C homogenizer, and
RNA was isolated following the manufacturer’s instructions.
Purified RNA pellets were thoroughly resuspended in Ultra-
Pure water (Sigma-Aldrich) on ice. RNA concentrations
were determined at 260 nm using a Beckman DU800
spectrophotometer.
Using 1–2 g of RNA, cDNA was synthesized using the
qScript cDNA Supermix (Quant BioSciences) according to the
manufacturer’s instructions. Quantitative real-time PCR was
performed using the Applied Biosystems 7500 Fast Real Time
PCR system with Fast Start Universal SYBR Green Master Mix
(Roche Applied Science) according to the manufacturer’s
instructions. Reactions were set up in triplicate using a 1-g/l
cDNA template. Following amplification, Ct values were
obtained from Applied Biosystems sequence detection soft-
ware, and the 	Ct values were determined for the gene of inter-
est compared with that for mouse GAPDH for each animal run
as a control. For each tissue the percent relative abundance of
mouse PCPE2 and PCPE1 was derived from the 	Ctmax  	Ct/
	Ctmax)  100. Primers designed using the Universal Probe
Library were purchased from Integrated DNA Technologies.
The following are the mouse sequences used: SR-BI forward,
GCCCATCATCATCTGCCAACT, and reverse, TCCTGGG-
AGCCCTTTTTACT; PCPE1 forward, TTACGTGGCAAGT-
GAGGGTTT, and reverse, TGTCCAGATGCACTTCTTGT-
TTG; and PCPE2 forward, TCACATGTGGCGGCATTCT,
and reverse, CAGGAAAACCTTCACTGCCAAT.
Immunoblotting—Immunoblotting was performed subse-
quent to total tissue protein isolation following extraction using
a radioimmune precipitation assay buffer (RIPA, Cell Signaling
Technologies) or using detergent-free lipid raft isolation as
described. For tissues extracted with radioimmune precipita-
tion assay buffer, aliquots of equal protein content were run on
12% SDS-PAGE. All sample aliquots were diluted with 4 LDS
buffer (Novex) to which solid DTT had been added to achieve a
100 mM final concentration. Samples were heated to 70 °C for
10 min. Transfer to PVDF membrane (PerkinElmer Life Sci-
ences) was accomplished after treatment with Tris-glycine, pH
8.3, buffer using a semi-dry blot (Bio-Rad) apparatus for 30 min
at 10 V. Membranes were blocked with 5% nonfat dry milk in 10
mM Tris-glycine, pH 7.4, buffer and processed. The primary
antibodies used (PCPE1 (Novus Biologicals), PCPE2 (Abcam),
GAPDH (Ambion), and SR-BI (Novus Biologicals)) were
diluted 1:1000 and incubated with the membrane at 4 °C over-
night. The blots were washed and then incubated with an HRP-
conjugated anti-mouse IgG secondary antibody (GE Health-
care) at a 1:10,000 dilution for 1 h at room temperature. Blots
were washed again and then incubated with SuperSignal West
Pico chemiluminescence substrate (Pierce) and visualized with
a FujiFilm LAS-3000 camera. Band intensities were compared
using MultiGauge software (FujiFilm).
HDL ApoA-I Turnover—Diet-fed mouse HDL was purified
using a combination of ultracentrifugation and FPLC. The puri-
fied HDL apoA-I was then labeled with 125I using the Mc-
Farlane method (57) as described previously (58, 59). Sufficient
ICl was used to have 0.5 mol of radiolabeled iodine for every
mole of HDL apoA-I and prevent damage to the protein or
labeling lipid. Labeled HDL apoA-I was purified from free
iodine using a desalting column (Bio-Rad), and the eluate was
dialyzed exhaustively against 0.15 M NaCl, pH 7.4. On the day of
the study, anesthetized mice were retro-orbitally injected with
125I-radiolabeled HDL (10  106 cpm) after isoflurane admin-
istration. Approximately 30 l of blood was collected from the
contralateral retro-orbital sinus at 0.08, 0.17, 0.5, 1, 3, 6, 22, 28,
and 48 h. Radioactivity was measured at each time point using a
Beckman Gamma 4000 counter. The fractional catabolic rates
and half-lives of the 125I-labeled HDL were determined from
plasma decay curves assuming a one-pool model (58). Blood
volumes were estimated to be 5.85 ml/100 g of body weight.
Histology and Immunofluorescence Microscopy—At the time
of sacrifice, a 21-gauge butterfly needle was inserted into the
left ventricle; the atrium was clipped, and the heart and aorta
were perfused with saline for 5 min and then removed and
cleaned of fat and adventitia. Mouse heart and aorta were
embedded in optimal cutting temperature (OCT) medium and
then sectioned for staining and immunohistochemistry. For
quantification of total and percent lesion area, OCT-embedded
aortas were cut into sequential 6-m sections using a Leica
cryostat at 50 °C. Tissue sections were stained overnight in
0.5% Oil Red O dissolved in propylene glycol and then counter-
stained with hemotoxylin. Masson’s trichrome stain was used
to assess the connective tissue content of the aortic root. Sec-
tions were digitized using a Nikon microscope and Image-Pro
Plus 6.2 software and then quantified using NIS-Elements soft-
ware (Nikon Instruments Inc.). Eight to 10 sections at intervals
of 30 m were used for morphological analyses and were aver-
aged to obtain a value for each animal. The results are expressed
as both the percentage of lesion area and absolute lesion area.
For immunofluorescence microscopy, purified rat anti-
mouse CD68 (AbD FA-11-Serotec) at a 1:100 dilution was used
as the primary antibody. Slides were incubated for 1 h in PBS
buffer containing 2% fetal calf plasma, washed with PBS, and
then incubated with a 1:300 dilution of Cy3-conjugated goat
anti-rat IgG antibody (Rockland) for 30 min at room tempera-
ture. After the slides were washed briefly with PBS, they were
stained with DAPI to visualize the nuclei and then mounted
with Fluoro-Gel (Electron Microscopy Sciences). Immunofluo-
rescence was visualized using a Nikon Eclipse TE2000-S micro-
scope, and the total and percentage of CD68 staining was quan-
tified using NIS-Elements software.
Picrosirius red staining of mouse tissues was performed on
formalin-fixed tissue embedded in paraffin and then cut serially
in 6-m sections. Collagen fibers were stained using picrosirius
red (Polysciences Inc.) and viewed with polarized light as
described (60).
PCPE2 Modulates SR-BI Function and Atherosclerosis
JUNE 19, 2015 • VOLUME 290 • NUMBER 25 JOURNAL OF BIOLOGICAL CHEMISTRY 15499
 by guest on N
ovem
ber 23, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
In Vivo Reverse Cholesterol Transport Studies—Diet-fed mice
received an intraperitoneal injection of 0.6  106 dpm of
[3H]cholesterol-labeled J774 cells as described previously (61).
Blood was collected at 6, 24, and 48 h, and the plasma was
counted for radioactive content (62). Feces collected from 0 to
48 h and subjected to lipid extraction were then counted for
radioactive content of neutral and acidic sterols as described
previously (63).
Tissue Culture and Transfection—CHO cells were grown in
DMEM/F-12 medium (1:1) supplemented with 10% (v/v) FBS,
100 units/ml penicillin, 100 g/ml streptomycin, and 2 mM
L-glutamine. Transient transfections were performed using
Lipofectamine 2000 according to the manufacturer’s protocol
(Life Technologies) with 2.5 g of DNA and 12 l of Lipo-
fectamine 2000/well of a confluent 6-well plate. The human
PCPE2-pCMV6 plasmid used in the transfection was obtained
from OriGene (Rockville, MD) and contains a Myc-DDK tag at
the N terminus, which adds 10 amino acids.
Selective Uptake of HDL Labeled with [3H]Cholesteryl Oleyl
Ether—HDL isolated as described above, using a combination
of ultracentrifugation and FPLC, was labeled with cholesteryl
[1a,2a-3H]oleoyl ether (3H-COE) (American Radiolabeled
Chemicals Inc.) using recombinant cholesterol ester transfer
protein (CETP, Roar Biomedical Inc.) as described (64). An ali-
quot containing 10 g of labeled HDL (based on protein)/ml of
plasma-free DMEM medium plus 0.5% BSA was incubated with
confluent CHO cells in a 6-well plate at 37 °C for 1.5 h. After
incubation the medium was removed, and the cells were
washed extensively to remove surface-bound labeled HDL. The
cell monolayer was lysed with 1 ml of 0.1 N NaOH, and aliquots
of the lysed cells were counted for their 3H radioactivity content
and normalized to total cell protein as determined by the Lowry
assay (65).
Surface Staining of CHO Cells—Transfected CHO cells were
harvested from 6-well plates and stained for SR-BI and PCPE2
using fluorescence-activated cell sorting (FACS) as described
previously (66). Briefly, 3  105 cells were stained with poly-
clonal rabbit anti-SR-BI-APC conjugate (Alexa Fluor 647)
(Bioss Antibodies) and mouse anti-MycDDK-FITC conjugate
(Alexa Fluor 488) (AbD Serotec) for 30 min at 4 °C. Samples
were washed and resuspended in 2% paraformaldehyde in PBS
before acquisition of samples using a system (BD Biosciences).
Statistical Analysis—GraphPad Prism version 5 was used for
statistical analysis, and the data are reported as mean  S.D.
Differences between groups were evaluated by independent t
tests and by analysis of variance with Tukey’s post hoc test.
Results
The Absence of PCPE2 Affects Lipoprotein Distribution and
Concentration—PCPE2-deficient mice in the C57BL/6 back-
ground (43) were characterized with respect to HDL size and
concentration for comparison with the previously published
phenotype (44). Fig. 1A shows the cholesterol distribution fol-
lowing FPLC separation of the major lipoprotein classes from
the d  1.225 g/ml density fraction. We see that PCPE2-defi-
cient mice possess a greater concentration of enlarged HDL
particles (Fig. 1A, dashed line) compared with control C57BL/6
mice that express PCPE2 (solid line). The increase in the HDL
cholesterol concentration in PCPE2-deficient mice was accom-
panied by an elevation in plasma apoA-I concentrations as
shown in Table 1. These changes in HDL levels were indepen-
dent of statistically significant changes in LDL or VLDL choles-
terol levels between genotypes. A trend to higher plasma trig-
lycerides was observed for chow-fed PCPE2-deficient mice, as
exemplified by the increased VLDL peak in Fig. 1A, but the
trend was not statistically significant. Non-denaturing gradient
gel separation confirmed that PCPE2/ mice had larger HDL
particle sizes and diameters compared with HDL from control
mice, as shown in Fig. 1B and consistent with the previous study
(44). The cholesterol to apoA-I composition was determined in
HDL particles purified by a combination of density ultracentri-
fugation and FPLC. Fig. 1C shows that HDL particles from
PCPE2/ mice were enriched in total cholesterol when nor-
malized to apoA-I content, likely accounting for the increase in
particle size. However, HDL from both genotypes had similar
ratios of esterified to total cholesterol (Fig. 1C, EC/TC), sug-
gesting that plasma lecithin-cholesterol acyltransferase activity
was similar for the two genotypes and that conversion of free
cholesterol to esterified cholesterol was not involved in particle
enlargement.
To investigate the atherosclerotic properties of PCPE2 HDL,
PCPE2-deficient mice were crossed with the hypercholester-
olemic LDL receptor-deficient (LDLr/) mouse, to create
LDLr/, PCPE2/ mice. Aliquots of plasma from 12 weeks
chow-fed LDLr/, PCPE2/ mice were centrifuged to obtain
the d  1.225 g/ml lipoprotein fraction, which was then sepa-
rated into lipoprotein classes by FPLC. Fig. 1D shows the lipo-
protein cholesterol distribution for LDLr/, PCPE2/
(dashed line) and LDLr/ mice (solid line). As anticipated,
HDL from LDLr/, PCPE2/ mice contained larger sized
particles, indicated by elution in earlier eluting fractions as seen
in PCPE2/ mouse plasma (Fig. 1A). The HDL cholesterol
concentration in LDLr/, PCPE2/ mice was also signifi-
cantly increased compared with LDLr/ mice, as shown in
Table 2.
Lipoprotein cholesterol distribution was then evaluated after
feeding an atherogenic diet (46, 47, 67) for 12 weeks (results
shown in Fig. 1E). As expected, both LDLr/, PCPE2/ and
LDLr/ mice had substantial increases in VLDL and LDL cho-
lesterol levels. Table 2 shows a comparison of these values with
their chow-fed counterparts. Interestingly, although diet-fed
LDLr/, PCPE2/ mice did not show a significant difference
in LDL cholesterol concentrations between genotypes, there
was a statistically significant increase (90%) in VLDL and
HDL cholesterol concentration. These results suggest that
feeding an atherogenic diet to hypercholesterolemic mice that
lack PCPE2 appears to also affect VLDL in addition to HDL
metabolism.
PCPE2 Protects against Diet-induced Atherosclerosis—
Groups of male LDLr/, PCPE2/, LDLr/, and LDLr/,
apoA-I/ mice were fed an atherogenic diet. After 12 weeks of
diet feeding their hearts and aortas were embedded into OCT,
sectioned, and stained with Oil Red O. The extent of athero-
sclerotic lipid accumulation was assessed by staining aortic root
sections with the neutral lipid stain followed by quantification,
as shown in Fig. 2A. Representative Oil Red O-stained aortic
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root sections are displayed from left to right from LDLr/,
LDLr/, PCPE2/, and LDLr/, apoA-I/ mice, respec-
tively. The neutral lipid staining is expressed as the percent Oil
Red O lesion area in Fig. 2B and as total Oil Red O lesion area as
m2 in Fig. 2C. These data indicate that the LDLr/,
PCPE2/ mouse aorta showed a statistically significant 46%
increase in aortic lipid accumulation compared with LDLr/
mice, regardless of how the lesion area was expressed. Interest-
ingly, LDLr/, PCPE2/ mouse aortic roots accumulated as
much neutral lipid as did diet-fed LDLr/, apoA-I / mice
(46, 47, 67), which do not express any apoA-I and lack tradi-
FIGURE 1. PCPE2 deficiency alters lipoprotein cholesterol and particle size. A, FPLC separation of the major lipoprotein classes expressed as cholesterol
concentration from representative age- and gender-matched C57BL/6 and PCPE2/ mice on a chow-fed diet. B, a Coomassie Blue-stained 4 –20% non-
denaturing gradient gel separation of a d  1.225 g/ml lipoprotein fraction from chow-fed C57BL/6 and PCPE2/ mice. C, top, the HDL composition as total
cholesterol (TC) to apoA-I mass ratio for HDL after FPLC isolation for each genotype. Bottom, the mass ratio of esterified cholesterol (EC) to total cholesterol as
determined by mass spectrometric analysis and an enzyme-linked immunosorbent assay as described under “Experimental Procedures.” D, FPLC separation of
the major lipoprotein classes expressed as cholesterol concentration from LDLr/ and LDLr/, PCPE2/ mice fed a chow diet. E, FPLC separation of the
major lipoprotein classes expressed as cholesterol concentration from 12 weeks atherogenic diet-fed LDLr/ and LDLr/, PCPE2/ mice. Data shown are
the mean of n  6 male mice for each genotype condition. Different letters in D indicate statistical significance at p  0.05.
TABLE 1
Plasma cholesterol and triglycerides
Fasting plasma cholesterol and triglyceride concentrations were obtained from
equal numbers of male and female mice fed a chow diet for 12 weeks.
Lipoprotein/Lipida C57BL/6 PCPE2/
mg/dl mg/dl
Plasma cholesterol 79  14b 121  29c
VLDL-C 3  1b 5  3b
LDL-C 14  3b 12  4b
HDL-C 55  8b 86  21c
Plasma triglycerides 69  11b 78  8b
ApoA-I 55  14b 98  18c
a Each lipoprotein cholesterol and apoprotein value represents the mean  S.D. of
n  6 mice/genotype. Lipoproteins were purified by a combination of ultracen-
trifugation and FPLC. Their lipid and protein content was determined as de-
scribed under “Experimental Procedures.” Statistical differences at p  0.05 for
each row are indicated by different letters.
TABLE 2
Chow diet versus atherogenic diet
Fasting plasma cholesterol and fasting triglyceride concentrations were obtained
from age-matched male mice fed a chow diet or an atherogenic diet for 12 weeks.
Lipoprotein/Lipidsa
Chow diet Atherogenic diet
LDLr/
LDLr/
PCPE2/ LDLr/
LDLr/
PCPE2/
mg/dl mg/dl mg/dl mg/dl
Total cholesterol 230  30b 300  34c 1248  109d 1520  50e
VLDL-C 5  1b 4  2b 448  252c 703  257d
LDL-C 92  7b 88  1b 583  209c 631  126c
HDL-C 48  6b 67  8c 52  11b 131  17d
Triglycerides 190  12b 230  30b 310  57d 601  43e
a Each lipoprotein cholesterol value represents the mean  S.D. of values from
n  6 mice/genotype. Lipoproteins were purified by a combination of ultracen-
trifugation and FPLC and their lipid content determined as described under
“Experimental Procedures.” Statistical differences at p  0.05 for each row are
indicated by different letters.
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tionally defined HDL particles in their plasma. Taken together,
these results show that higher concentrations of enlarged HDL
in LDLr/, PCPE2/ mice do not offer significant protection
against the progression of atherosclerosis. Furthermore, aortic
lipid deposition in LDLr/, PCPE2/ mice could not be dis-
tinguished from that seen in mice having no apoA-I-associated
HDL, suggesting that the HDL particles in LDLr/, PCPE2/
mice are dysfunctional in nature.
Staining for the presence of CD68 cells in the aortic root is
commonly used as a marker for macrophage infiltration. Rep-
resentative stained aortic root sections are shown in Fig. 2D:
LDLr/, LDLr/, PCPE2/, and LDLr/, apoA-I/ mice
displayed from left to right, respectively. CD68 staining is
expressed as the percent of CD68 area in Fig. 2E and as total
CD68 area in m2 in Fig. 2F. As observed with neutral lipid
staining, LDLr/, PCPE2/ and LDLr/, apoA-I/ mouse
aortas had about a 45% increase in CD68 staining cells com-
pared with aortas from LDLr/ mice.
Reduced Collagen Content in PCPE2-deficient Mice—Given
the reported enhancer properties of PCPE2 on BMP1 catalytic
function (68, 69), we measured the connective tissue content in
the aortic root using Masson’s trichrome. Fig. 3A shows repre-
sentative aortic roots sections from 12-week diet-fed LDLr/
and LDLr/, PCPE2/ mice. Adjacent to each section is the
quantification of the connective tissue content, as shown by
dark blue staining (Fig. 3A) for each genotype. Whether the
data were calculated as the percent of connective tissue area or
as total connective tissue area (m2), the LDLr/, PCPE2/
aorta had 28% less connective tissue than the LDLr/ aorta
using Masson’s trichrome staining. Because collagen types I
FIGURE 2. PCPE2 deficiency exacerbates atherosclerosis despite elevated HDL cholesterol levels. A, representative aortic root sections stained with Oil
Red O from 12 weeks atherogenic diet-fed LDLr/, LDLr/ PCPE2/, and LDLr/, apoA-I/ mice. B and C, quantification of the atherosclerotic lesion area
as a percentage of the total aortic area (B) and the total lesion area in m2 (C). D, representative aortic root sections stained with fluorescently labeled
antibodies to CD68, a macrophage marker, from 12 weeks atherogenic diet-fed LDLr/ mice, LDLr/,PCPE2/ mice, and LDLr/, apoA-I/ mice. E and F,
quantification of the macrophage content was performed by measuring CD68 staining over background as a percentage of the total lesion area (E) and of the
total lesion area in m2 (F). Data represent the mean  S.D. of n  10 male mice/group. Different letters indicate statistical significance at p  0.05. The
fluorescence background threshold was set to the intensity of sections receiving the fluorescently tagged secondary antibody but no CD68 primary antibody.
FIGURE 3. PCPE2 deficiency decreases collagen content in aorta and liver. A, representative aortic root sections following Masson’s trichrome staining.
Sections were obtained from LDLr/ and LDLr/, PCPE2/ mice fed an atherogenic diet for 12 weeks. Quantification of the absolute connective tissue area
and the percent of total collagen content per aortic area is shown adjacent to representative sections from each genotype. Data represent the mean  S.D. of
n  10 male mice/group. Different letters indicate statistical significance at p  0.05. B, representative aortic root sections following picrosirius red staining for
LDLr/ in a, c, and e and for LDLr/, PCPE2/ in b, d, and f. Bright field 5 images are shown in a and b. c–f, polarized images at 5 are shown in c and d and
in the blue boxed regions at 20 in e and f. C, relative mRNA abundance for PCPE2 and PCPE1 in artery (left) compared with the liver (right) for LDLr/ mice (gray
bar) and LDLr/, PCPE2/ (black bar) mice fed an atherogenic diet. D, representative sections of liver from an atherogenic diet-fed LDLr/ and LDLr/,
PCPE2 mouse stained with picrosirius red and viewed using polarized light to show the birefringence of the collagen fibers.
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and III are prevalent in mouse heart and aorta, it follows that
the regulation of procollagen processing must play an impor-
tant role in normal tissue maintenance during disease progres-
sion (70). The reduction in LDLr/, PCPE2/ aortic root
connective tissue was confirmed by the picrosirius red staining
of paraffin-embedded aortic root sections show in Fig. 3B, a–f.
In Fig. 3B, a, c, and e, different views are offered of a represen-
tative slide taken from LDLr/ mouse aortic root, whereas the
views in b, d, and f are from LDLr/, PCPE2/ mouse aortic
root. Fig. 3B, a and b, shows stained aortic root at 5 magnifi-
cation using light microscopy, and c and d panels show the same
slide but under polarizing filters. Fig. 3B, e and f, shows the same
slides as above but at a 20 magnification under polarizing
filters, as indicated by the boxed areas in c and d. The birefrin-
gence of collagen fibers under polarized light shows a shift in
color between the various components, red, orange, yellow, and
green, and represents the order of decreasing thickness of the
fibers. In this case, the LDLr/, PCPE2/ mouse aortic root
appears to have significantly less birefringence of all thicknesses
of collagen fibers when compared with the LDLr/ aortic root,
again confirming the results of the Masson’s trichrome stain-
ing. Because PCPE1 is highly similar in structure and function
to PCPE2 with respect to procollagen processing, we examined
whether the expression of PCPE1 might be elevated in the
PCPE2-deficient state. Fig. 3C compares PCPE1 and PCPE2
mRNA expression in the artery and liver from the two geno-
types of mice. No elevation of PCPE1 was seen in either tissue in
light of the absence of PCPE2, although these results do show
significant expression of both PCPE1 and PCPE2 in the liver of
LDLr/ mice.
Based on the mRNA expression data we then examined the
picrosirius staining of collagen fibers in the hepatic triad of
livers from LDLr/, PCPE2/ and LDLr / mice (shown in
Fig. 3D). Here, under polarizing light the picrosirius-stained
hepatic portal triad from LDLr/, PCPE2/ mice was com-
pared with that from LDLr/ mice and showed that both the
thickness and amount of collagen are significantly reduced in
LDLr/, PCPE2/ mice.
PCPE2 Was Not Essential for in Vivo Pro-apoA-I Processing—
PCPE2 had been reported to enhance the BMP1-mediated
cleavage of propeptides from procollagen (27, 29, 71) during
assembly in the extracellular matrix. These studies suggest that
cleavage of apoA-I’s propeptide is the rate-limiting step to form
nHDL (39, 71, 72) and the primary defect in PCPE2-deficient
mice. Investigators have hypothesized that if PCPE2 and BMP1
work together to remove the pro-segment of pro-apoA-I, then
HDL concentrations in mice lacking PCPE2 expression might
be affected. Francone et al. (44), having measured HDL apoA-I
from PCPE2-deficient mice by isoelectric focusing and mass
spectrometry, report an elevation in the amount of plasma pro-
apoA-I over mature apoA-I.
To investigate this effect further, we first measured the ratio
of intact pro-apoA-I to mature apoA-I in plasma HDL from
PCPE2-deficient mice by mass spectrometric analyses. Fig. 4, A
and B, shows the masses of directly infused delipidated apoA-I
from the plasma of C57BL/6 (A) and PCPE2/ mice (B),
respectively, after transformation of the electrospray spectrum.
These results demonstrate that in both samples the most abun-
dant mass was consistent with mature mouse apoA-I (27,950 
1.4 Da (73)), with only a small amount of mouse pro-apoA-I
(28,815  1.4 Da), which includes the mass of the pro-sequence
WHVWQQ.
To quantify the amount of pro-apoA-I in plasma, the unique
T1 peptide for the mature apoA-I (DEPQSQWDK) tryptic pep-
tide and T1 for pro-apoA-I (WHVWQQDEPQSQWDK),
which includes the additional six pro-amino acids, were syn-
thesized and used as standards. The sequence of each syn-
thetic peptide was verified by MS/MS sequencing, and then
LC/MS was used to establish the retention times and ionizabil-
ity of the two different T1 peptides. The ion-current ratio of
equal molar amounts of the two synthetic T1 peptides,
T1apoA-I/T1pro-apoA-I, was found to be 1.07.
Aliquots of mouse plasma were separated on 12% SDS-
PAGE. The gel band corresponding to apoA-I at 28,000 Da
was excised and subjected to in-gel digestion using trypsin (51).
Following digestion, peptides were exhaustively extracted from
the gel slice, separated by reverse-phase HPLC, and identified
by monitoring the 2 charge state of each peptide (566.75 m/z
for mature apoA-I and 998.95 m/z for pro-apoA-I). Fig. 4 shows
the summed selective ion electrospray mass chromatograms
for apoA-I from C57BL/6 (C) and PCPE2/ mouse plasma
(D). Note that the distribution of both pro- and mature apoA-I
was virtually identical for both genotypes. The critical factor for
this analysis is that the molar ion intensities of each peptide
were nearly identical; therefore, the measured ion intensities
could be used to quantify the relative amount of each peptide.
This interpretation of our data completely changes the inter-
pretation based on a previous study (44) that reported an ele-
vation in the amount of pro-apoA-I. Thus, our studies suggest
that the role of PCPE2 in HDL enlargement is not due to the
conversion of pro-apoA-I to mature apoA-I. Overall, we found
that both genotypes had very little (4%) pro-apoA-I, and these
results suggest that although PCPE2 may enhance pro-apoA-I
processing in vitro, in vivo the absence of PCPE2 does not
appear to be rate-limiting.
PCPE2 Affects HDL ApoA-I Catabolism Rates—To investi-
gate the possibility that increased concentrations of enlarged
HDL in plasma were related to the reduced catabolism of
plasma HDL in PCPE2-deficient mice, HDL was purified from
the plasma of diet-fed LDLr/ and LDLr/, PCPE2/ mice
using a combination of ultracentrifugation and FPLC and then
radiolabeled with 125I. Purified 125I-labeld HDL particles were
injected into diet-fed recipient mice, and the disappearance of
radioactivity from plasma was followed over time, as shown in
Fig. 5, A and B. 125I-labeled HDL from LDLr/ mice injected
into LDLr/ mice had a fractional catabolic rate (FCR) of
0.106  0.010 pools/h as compared with a FCR of 0.076  0.011
when the same HDL was injected into LDLr/, PCPE2/
mice (mean  S.D. of n  3 mice). A similar trend was observed
when 125I-labeled HDL from LDLr/, PCPE2/ mice was
injected into LDLr/ versus LDLr/, PCPE2/ mice,
resulting in an FCR of 0.097  0.030 versus 0.062  0.008,
respectively. From these data it appears the rate of turnover for
HDL isolated from LDLr/ or LDLr/, PCPE2/ mice was
a function of the recipient genotype and not a result of HDL
particle origin. In conclusion, these results suggest that PCPE2
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exerts its effects on HDL metabolism by assisting in particle
remodeling and/or removal. There was a trend suggesting that
the larger LDLr/, PCPE2/-derived HDL particles were
removed more slowly in both genotypes, but this trend did not
reach statistical significance.
PCPE2 and Reverse Cholesterol Transport—As PCPE2 is
expressed in the extracellular matrix of mouse liver (29), we
next determined how its absence might alter macrophage to
liver reverse cholesterol transport (61). To this end, atherogenic
diet-fed LDLr/ and LDLr/, PCPE2/ mice received an
intraperitoneal injection of [3H]cholesterol-loaded J774 foam
cells (61). The amount of [3H]cholesterol appearing in the
plasma and feces was measured for 0 – 48 h, and the results are
presented as the percent of injected dose (shown in Fig. 5, C and
D, respectively). Six hours after the [3H]cholesterol-loaded J774
cells were injected, there was a significant difference in the
appearance of [3H]cholesterol in plasma between the two gen-
otypes (Fig. 5C). LDLr/, PCPE2/ mouse plasma showed a
2-fold higher concentration of [3H]cholesterol, which
remained relatively constant over the course of the study. In
contrast, LDLr/ mice showed a comparatively slower
increase in plasma radioactivity, which reached a maximum by
24 h and then decreased by 48 h. The excretion of neutral
[3H]cholesterol in LDLr/ mouse feces was statistically
FIGURE 4. Mass spectrometric analysis and the ratio of mature to pro-apoA-I in HDL from PCPE2/ mouse plasma. A and B, molecular masses of HDL
apoA-I after maximum entropy transformation of the electrospray spectrum of FPLC purified HDL apoA-I from chow-fed C57BL/6 mice (A) and PCPE2/ mice
(B). The most abundant mass in each spectrum was identical within the 1.4 Da S.D. to the mass of mature mouse apoA-I at 27,950 Da. The minor spectrum
peak is consistent with the mass of mouse pro-apoA-I at 28,815 Da. C and D, the relative intensity of apoA-I tryptic peptides from LC-MS/MS analysis. ApoA-I
from whole mouse plasma was separated by 12% SDS-PAGE followed by in-gel trypsin digest and then analyzed for the N-terminal tryptic pro-apoA-I peptide
and mature apoA-I peptide: C57BL/6 mouse plasma (C) and PCPE2/ mouse plasma (D) as described under “Experimental Procedures.” Peptides were
separated by reverse-phase HPLC and analyzed for tryptic peptide of the N-terminal T1 for mature peptide (m/z 1132.48) and the T1 propeptide (m/z 1995.88),
shown in selective ion chromatograms. The mature murine T1 tryptic peptide has the amino acid sequence DEPQSQWDK, and the unprocessed pro-form has
the sequence WHVWQQDEPQSQWDK.
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greater than that in LDLr/, PCPE2/ mouse feces (Fig. 5D).
Although a trend for greater 3H acidic sterol excretion was seen
for LDLr/ compared with LDLr/, PCPE2/ mice, it was
not statistically significant. Together, the plasma and fecal anal-
yses indicate that in the absence of PCPE2 less macrophage
cholesterol was removed by the RCT pathway to the liver.
Although RCT consists of multiple steps, it is largely depen-
dent on the expression of hepatic SR-BI (74). It is also known
that attenuation of SR-B1 in mice results in a substantial
increase in HDL plasma levels (10). Based on these facts, we
next examined the expression of SR-BI in the liver of LDLr/,
PCPE2/ mice by both RT-PCR and Western blot analysis
(shown in Fig. 5, E and F). Here an immunoblot probing for mouse
SR-B1 using liver extracts from two different mice per genotype
shows that SR-B1 levels in LDLr/, PCPE2/ mice are approx-
imately twice that in LDLr/ mouse livers, whereas GAPDH lev-
els are constant. These findings were further supported by RT-
PCR analysis showing a greater abundance of SR-BI mRNA in liver
from LDLr/, PCPE2/ mice compared with controls (Fig. 5F),
suggesting that both SR-B1 mRNA, as well as protein, is up-regu-
lated in the LDLr/, PCPE2/ mouse liver. This outcome was
unexpected because our earlier results showed a reduction in RCT
and HDL catabolism, consistent with a reduction in SR-BI. These
results led us to focus next on measuring the effect of PCPE2
expression on SR-BI function.
PCPE2 Enhances SR-BI Cholesteryl Ester Uptake Function—
To determine how PCPE2 expression might affect SR-BI func-
tion, we first considered testing primary hepatocytes from
LDLr/, PCPE2/ and control mice. However, the presence of
PCPE2 in the extracellular matrix was not compatible with the use
of collagenase during hepatocyte isolation. In addition, reports
cautioning against the use of primary hepatocytes when studying
SR-BI regulation (75) led us to perform a gain of function study in
CHO cells (76). To test the effect of PCPE2 on SR-BI-mediated
HDL-cholesteryl ester uptake, we first determined the surface
expression of PCPE2 in CHO cells that were either mock-trans-
fected or transfected with a plasmid expressing PCPE2 for 24 h.
Fig. 6A shows a histogram of PCPE2 surface expression 24 h
after transfection measured by flow cytometry. The dotted line
depicts the expression of PCPE2 in control cells, and the shaded
solid line depicts the shift in PCPE2 surface expression in
PCPE2 transiently transfected CHO cells (Fig. 6A). The 2-fold
increase (47926  1025 versus 21336  525, mean  S.D., n 
3 independent experiments) indicates that PCPE2 transfection
significantly increased its expression on the cell surface, consis-
tent with the known function of PCPE2 in the extracellular
matrix.
Next, to test the effect of PCPE2 on SR-BI function, CHO
cells were mock-transfected or transfected with a construct
encoding PCPE2 and then assayed for their ability to take up
FIGURE 5. Absence of liver PCPE2 affects HDL-mediated reverse cholesterol transport and SR-BI expression. A, HDL from diet-fed LDLr/ and LDLr/,
PCPE2/ mice was purified and then radiolabeled with 125I as described under “Experimental Procedures.” Approximately 10  106 cpm of 125I-labeled HDL
was retro-orbitally injected into atherogenic diet-fed recipient mice of the indicated genotype. Blood was collected from the contralateral retro-orbital sinus
at the indicated times. B, the FCR of 125I-labeled HDL were determined from plasma decay curves assuming a one-pool model as described under ”Experimental
Procedures.” Data represent the mean  S.D. of n  3 mice/group. C, [3H]cholesterol levels in plasma during macrophage reverse cholesterol transport study
in LDLr/ (gray circles) and LDLr/, PCPE2/ (black squares) mice fed an atherogenic diet. Mice were injected intraperitoneally with [3H]cholesterol-labeled
J774 foam cells as described under “Experimental Procedures.” D, [3H]cholesterol in feces after 0 – 48 h collection. The numerical data shown is the mean  S.D.
of n  5– 6 male mice for each genotype. The asterisk indicates statistical significance at p  0.001. ns, indicates that the difference was not significant. E, an
immunoblot analysis of liver SR-BI levels in atherogenic diet-fed mice. F, relative mRNA abundance of liver SR-BI in atherogenic diet-fed mice. Data represent
the results from n  6 –10 male mice/genotype. The liver mRNA abundance of SR-BI in LDLr/ mouse liver was set at 100%.
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HDL-cholesteryl ester. The day after mock or transient trans-
fection with PCPE2, confluent cell monolayers were washed
and then incubated with 10 g of labeled 3H-COE HDL for 1.5 h
in triplicate. Following incubation, the monolayer was washed
extensively and the cell pellet subjected to radioactivity and
protein quantification. Fig. 6B shows the results of these studies
and suggests that the overexpression of PCPE2 enhanced the
uptake of 3H-COE HDL. This increase in SR-BI function
appeared to be independent of HDL origin, because HDL par-
ticles derived from either LDLr/ or LDLr/, PCPE2/
mice showed a similar extent of 3H-COE uptake.
We next examined the protein extracts from cells that were
either mock-transfected or transfected with PCPE2 using
immunoblot analysis, as shown in Fig. 6C. In this study, the total
cellular SR-BI protein was unchanged by PCPE2 overexpres-
sion. PCPE2 protein levels were increased with overexpression,
as identified by the 1.2-kDa increase in the endogenous molec-
ular mass due to the MycDDK tag on the exogenously
expressed PCPE2.
To further explore the mechanism behind PCPE2 enhance-
ment of SR-BI function, mock- and PCPE2-transfected CHO
cells were stained and analyzed for SR-BI surface expression
using flow cytometry. Fig. 6D shows a histogram of surface
SR-BI expression in control cells, indicated by the dotted line,
and in cells overexpressing PCPE2, denoted by a solid line.
Interestingly, the control cells contain two populations of cells,
one characterized by a low surface frequency of SR-BI/cell and
a second population with a significantly higher frequency of
SR-BI/cell. Upon overexpression of PCPE2, a shift to one pop-
ulation with a significantly higher frequency of SR-BI/cell is
observed (50992  1070 versus 36244  905, mean  S.D., n 
3 independent experiments). These results suggest that PCPE2
may act to enhance SR-BI function by promoting or maintain-
ing SR-BI expression on the cell surface.
Discussion
The current studies show for the first time that PCPE2, an
extracellular matrix-associated protein, confers an atheropro-
tective function to HDL in vivo. The implication is that in the
absence of PCPE2, HDL particles are dysfunctional and cannot
protect against the progression of atherosclerosis. In addition,
these studies show that the apparent HDL dysfunction results
FIGURE 6. SR-BI functionality is enhanced in the presence of PCPE2. A, a histogram of PCPE2 cell surface expression by flow cytometry. CHO cells were either
mock-transfected or control CHO cells (dotted line) or transiently transfected with PCPE2 (shaded solid line). The next day the cells were stained for surface PCPE2
expression as described under “Experimental Procedures.” A 2-fold increase (47926  1025 versus 21336  525, mean  S.D., n  3 independent experiments)
in PCPE2 surface expression in transiently transfected cells is consistent with the PCPE2 known location in the extracellular matrix. B, the uptake of 3H-COE-
labeled HDL by control and PCPE2-overexpressing CHO cells expressed as ng of HDL taken up/mg of cell protein. Confluent wells of CHO cells were either
mock-transfected or transfected with a plasmid encoding PCPE2 as described under “Experimental Procedures.” The next day the cells were washed and then
incubated for 1.5 h with 10 g of 3H-COE-labeled HDL obtained from either diet-fed LDLr/ or LDLr/, PCPE2/ mouse plasma as described under
“Experimental Procedures.” The cells were washed extensively, and then the cell pellet was digested in 0.1 N NaOH and its protein and radioactivity content
quantified as described under “Experimental Procedures.” Each value represents the mean  S.D. of n  3 wells/condition from three independent experi-
ments. C, an immunoblot of SR-BI and PCPE2 protein expression from control and PCPE2-overexpressing CHO cells. Each lane contains 25 g of total protein.
D, a histogram of SR-BI surface expression in mock (dotted line)- and PCPE2-transfected CHO (shaded solid line) cells by flow cytometry. Overexpression of PCPE2
leads to a shift to a single population, with a significantly higher frequency of SR-BI per cell (50992  1070 versus 36244  905, mean  S.D., n  3 independent
experiments).
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from reduced HDL-CE catabolism via SR-BI and is not actually
due to changes within the particle or its components itself (Fig.
5, A–D). Surprisingly, the extent of atherosclerosis in LDLr/,
PCPE2/ mice was indistinguishable from that in LDLr/,
apoA-I/ mice, which lack all apoA-I-containing HDL parti-
cles (47). Although both LDLr/, PCPE2/ and LDLr/,
apoA-I/ mice had similar extents of atherosclerosis, there
was an uncoupling of its progression as it relates to total plasma
cholesterol levels (77). LDLr/, apoA-I/ mice had no HDL
and half the circulating LDL cholesterol levels as diet-fed
LDLr/ mice (46). In contrast, LDLr/, PCPE2/ mice had
higher HDL cholesterol concentrations and similar LDL cho-
lesterol concentrations relative to LDLr/ mice but increased
atherosclerosis. These findings suggest that the term “dysfunc-
tional HDL,” e.g. HDL that is not atheroprotective, does not
technically apply in this situation. Rather, HDL-related dys-
functionality was caused by obstruction of the RCT at one or
more of its individual steps.
There are several mechanistic scenarios for the role of
PCPE2. The first is that PCPE2 confers atheroprotection to
apoA-I by enhancing BMP1-mediated catalytic cleavage, con-
verting pro-apoA-I to mature apoA-I, and stimulating ABCA1-
mediated cholesterol flux (26, 44). However, our studies show
conclusively that pro-apoA-I processing was not altered in the
case of PCPE2 deficiency (Fig. 4). The absence of PCPE2 did not
affect the circulating levels of pro-apoA-I in vivo, which
remained around 3– 6% of total apoA-I for both PCPE2-replete
and PCPE2 knock-out mice. Although PCPE2 enhanced pro-
apoA-I processing in vitro and was shown to have a high affinity
for apoA-I using both surface plasmon resonance and selective
co-immuno-precipitation (26), its absence in vivo did affect the
ratio of pro- to mature apoA-I. This was not unexpected,
because PCPE2 is not essential for catalytic cleavage of pro-
apoA-I by BMP1 (39, 42). Theoretically, PCPE2 may limit
BMP1-mediated processing of pro-apoA-I under high sub-
strate conditions, as reported for the processing of procollagen
in the heart following chronic pressure overload (70).
Insight into the molecular mechanism of the protective func-
tion of PCPE2 comes from our HDL clearance studies (Fig. 5, A
and B), where the fractional clearance of HDL was delayed in
PCPE2-deficient mice, regardless of the source of the HDL. A
slower catabolic turnover resulted in increased HDL concen-
tration, which ultimately caused HDL particle enlargement
(Fig. 1). In mice, increased HDL size and concentration is a
hallmark of SR-B1 deficiency (78). Hepatic specific SR-B1-de-
ficient mice were reported to have higher plasma HDL levels
than the controls, with greater aortic lesion formation. Because
hepatic SR-B1 mediates selective uptake of HDL-cholesteryl
esters and their removal from circulation for excretion into bile
(74), it was concluded that in mice SR-BI is a positive regulator
of macrophage RCT. As seen in genetically modified mice,
humans with genetic variants in SR-BI show a reduced capacity
to efflux CE, which leads to greater HDL plasma concentrations
(79 – 82) and a greater risk for CVD. Our study showed a
macrophage to fecal RCT rate significantly lower in LDLr/,
PCPE2/ mice and similar to that reported for SR-BI knock-
out mice. Interestingly, this lower rate occurred despite a 2-fold
higher level of SR-BI protein in the livers of LDLr/,
PCPE2/ mice (Fig. 5, C–F).
The impact of PCPE2 on liver SR-BI functionality was dem-
onstrated by slower plasma HDL-CE turnover, reduced macro-
phage cholesterol to fecal deliver, and increased plasma HDL
size and concentration. Despite elevations in plasma HDL, the
aortic lipid and immune cell infiltration was greater in the
absence of PCPE2, highlighting the importance of aortic SR-BI
in preventing the progression of atherosclerosis. These results
prompted us to consider how PCPE2 might influence hepatic
SR-BI function.
Transient transfection of CHO cells with PCPE2 gave a
2-fold increase in PCPE2 surface expression (Fig. 6, A and C)
and an almost 2-fold increase in the uptake of 3H-COE from
labeled HDL (Fig. 6B). Overexpression of PCPE2 in CHO cells
did not change total SR-BI protein levels but did increase the
amount of SR-B1 protein measured on the surface of trans-
fected cells (Fig. 6D). In contrast, liver SR-BI expression in
PCPE2 knock-out mice was increased 2-fold. The absence of an
increase in SR-B1 protein following transfection may be
ascribed to the transient nature of the in vitro experiment.
Our studies also provide evidence for a profound reduction
in connective tissue content in both the aortic root and the
hepatic triad in mice lacking PCPE2 (Fig. 3, A–D). PCPE2
enhances procollagen processing and is abundantly expressed
in the heart, aorta, adipose tissue, and trabecular meshwork (27,
29, 38). The expression of PCPE1, which is related to PCPE2,
was not increased as a result of PCPE2 deletion (Fig. 3, C and D)
and did not substitute for PCPE2 in arterial tissue. The conse-
quences of these changes in connective tissue content are not
known at this time but may be related to the positioning and or
stabilization of SR-B1 on the cell surface.
The mechanistic steps involved in SR-BI-mediated aortic
cholesterol homeostasis have been studied for years, but ques-
tions still remain. How SR-B1 mediates selective CE removal
from HDL at the cell surface, leaving lipid-poor apoA-I after
transferring CE into the cell, remains unresolved. Nevertheless
our results strongly suggest that SR-BI-mediated 3H-COE
removal from HDL is facilitated by surface-bound PCPE2. The
mechanism of the influence of PCPE2 on SR-BI uptake of
HDL-CE may involve promoting the oligomerization of SR-BI
with itself, with PCPE2, or with other proteins. Previous studies
have demonstrated that SR-BI forms dimers and tetramers on
the cell surface necessary for its function (83– 85). Oligomeri-
zation has been postulated to form a hydrophobic channel that
facilitates the selective delivery of CE from HDL to the cell.
Although putative SR-BI oligomerization domains are thought
to localize to the transmembrane segment, it has been sug-
gested that the extracellular domains of SR-BI may also con-
tribute to oligomerization (86). The shift in SR-BI surface stain
intensity (Fig. 6D) suggests a significant change in antibody
binding properties and, therefore, a change in the conformation
of amino acid region 338 – 440.
Alternative explanations for the action of PCPE2 on SR-BI
include the postulation that PCPE2 binds and sequesters SR-B1
at the cell surface. Previous studies have reported that the intra-
cellular adaptor protein PDZK1 binds the C terminus of SR-BI
and is required for receptor function (87, 88). In an analogous
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way, PCPE2 may provide scaffolding or tethering at the cell
surface, promoting association of SR-B1 with HDL-CE.
Another possibility would be that PCPE2 is involved in SR-BI
endocytosis (89 –92). Yet another plausible mechanism is based
on the previously shown ability of PCPE2 to bind apoA-I (26);
here PCPE2 would interact with apoA-I bound to HDL, thereby
altering the protein conformation and in turn enhancing CE
removal. As the current report provides a solid foundation for
our understanding of PCPE2 function, additional studies will be
needed to examine the structures of and potential interactions
between PCPE2 and SR-BI, allowing insights into the mecha-
nisms through which PCPE2 controls SR-BI-mediated
HDL-CE uptake.
In conclusion, our studies show for the first time that an
extracellular matrix protein, PCPE2, is essential for the integ-
rity of the HDL-mediated CE transport system. These studies
also show that simply measuring plasma HDL concentration or
its associated components in order to assess one’s risk of CVD
can be misleading. Rather, a combination of HDL production,
catabolism, and concentration is essential for a precise analysis
of HDL function. The novel finding is that PCPE2 contributes
to SR-BI function by enhancing the rate of HDL-CE uptake,
thereby stimulating the RCT pathway. Because the molecular
events that drive the selective uptake of CE from HDL particles
via SR-BI have yet to be completely delineated, the questions
generated by this work will lead to new studies designed to
define those mechanisms. Overall, these studies will ultimately
lead to a precise understanding of how SR-BI mediates selective
CE uptake and provide new insights into how extracellular
matrix-associated proteins, such as PCPE2, protect against the
development of atherosclerosis.
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